Skip to main content
SpringerLink
Log in

Funding new drugs at list prices would result in high excess costs for Ireland

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Health Services Executive

Reference

  • Kennedy C, et al. Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Value in Health : 18 May 2021. Available from: URL: https://doi.org/10.1016/j.jval.2021.03.012

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Funding new drugs at list prices would result in high excess costs for Ireland. PharmacoEcon Outcomes News 879, 13 (2021). https://doi.org/10.1007/s40274-021-7736-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7736-6

Search

Navigation